Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. L. Davis · SciRah

Researcher profile · Semantic Scholar

S. L. Davis

Share profile

S. L. Davis — researcher profile on SciRah

h-index: 15
Works: 69
Citations: 661

Most-cited papers

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
A. Capasso, J. Lang, T. Pitts, Kimberly R. Jordan +13 more
2019Journal of Immunotherapy for Cancer156 citations Open access
Semantic Scholar
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
M. Yarchoan, L. Cope, Amanda N. Ruggieri, R. Anders +25 more
2021Journal of Clinical Investigation66 citations Open access
Semantic Scholar
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers
S. L. Davis, S. G. Eckhardt, J. Tentler, Jennifer R. Diamond
2014Therapeutic Advances in Medical Oncology41 citations Open access
Semantic Scholar
Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
M. Borad, L. Bai, D. Richards, K. Mody +11 more
2022Hepatology30 citations Open access
Semantic Scholar
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
A. Krishnamurthy, A. Dasari, Anne M. Noonan, J. Mehnert +16 more
2018Cancer Research29 citations Open access
Semantic Scholar
Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: a multicenter retrospective analysis.
Lawrence Kogan, S. L. Davis, G. Brooks
2019Journal of Gastrointestinal Oncology28 citations Open access
Semantic Scholar
Antitumor Activity of the MEK Inhibitor TAK-733 Against Melanoma Cell Lines and Patient-Derived Tumor Explants
Lindsey N. Micel, J. Tentler, A. Tan, H. Selby +10 more
2014Molecular Cancer Therapeutics26 citations Open access
Semantic Scholar
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
S. L. Davis, Kelli M. Robertson, T. Pitts, J. Tentler +11 more
2015Frontiers in Pharmacology25 citations Open access
Semantic Scholar
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
S. L. Davis, S. Hartman, S. Bagby, Marina I. Schlaepfer +11 more
2022BMC Cancer24 citations Open access
Semantic Scholar
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
S. Hartman, S. Bagby, Betelehem Yacob, Dennis M. Simmons +9 more
2021Frontiers in Oncology23 citations Open access
Semantic Scholar
A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.
H. Burris, M. Gordon, M. Hellmann, P. LoRusso +16 more
201722 citations
Semantic Scholar
Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study.
A. Oba, Y.-Ha Wu, C. Lieu, C. Meguid +18 more
2021British Journal of Surgery21 citations
Semantic Scholar
Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.
M. Borad, Li-Yuan Bai, Ming-Huang Chen, J. Hubbard +16 more
202121 citations
Semantic Scholar
Biomarkers to predict immune-related adverse events with checkpoint inhibitors.
L. Head, N. Gorden, Robert J. Van Gulick, C. Amato +5 more
2019Journal of Clinical Oncology18 citations
Semantic Scholar
Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
G. King, Paramanand Sharma, S. L. Davis, A. Jimeno
2018Drugs of Today15 citations
Semantic Scholar
Abstract CT043: A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study
M. Yarchoan, L. Cope, R. Anders, A. Noonan +21 more
2020Tumor Biology13 citations
Semantic Scholar
The impact of young adult colorectal cancer: incidence and trends in Colorado
David W. Sheneman, J. Finch, W. Messersmith, S. Leong +8 more
201711 citations Open access
Semantic Scholar
A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer
S. L. Davis, S. Eckhardt, J. Diamond, W. Messersmith +7 more
2018The Oncologist9 citations Open access
Semantic Scholar
High incidence of prolonged rectal bleeding and advanced stage cancer in early-onset colorectal cancer patients
G. Sandhu, R. Anders, P. Blatchford, A. Walde +23 more
20208 citations Open access
Semantic Scholar
Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers
N. Kastelowitz, Megan D. Marsh, M. McCarter, R. Meguid +18 more
2021Frontiers in Oncology7 citations Open access
Semantic Scholar
Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).
C. Lieu, S. L. Davis, S. Leong, Alexis D. Leal +16 more
2020Journal of Clinical Oncology7 citations
Semantic Scholar
Abstract B48: A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.
S. L. Davis, P. LoRusso, Lu Xu, A. Kapoun +4 more
20137 citations
Semantic Scholar
Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy.
M. Borad, S. L. Davis, M. Lowery, C. Lihou +1 more
20176 citations
Semantic Scholar
Current Practice in Carcinoid Heart Disease and Burgeoning Opportunities.
Carrie Lenneman, D. Harrison, S. L. Davis, Lavanya Kondapalli
2022Current Treatment Options in Oncology5 citations
Semantic Scholar
High incidence of advanced stage cancer and prolonged rectal bleeding history before diagnosis in young-onset patients with colorectal cancer.
G. Sandhu, R. Anders, A. Walde, A. Leal +16 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer.
S. L. Davis, D. Cardin, S. Shahda, H. Lenz +7 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors
P. Munster, S. Eckhardt, A. Patnaik, A. Shields +8 more
20154 citations
Semantic Scholar
Metastatic Colorectal Cancer: Focus on Panitumumab
S. L. Davis, A. Jimeno
20104 citations
Semantic Scholar
Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.
J. Kagihara, B. Corr, J. Pacheco, S. L. Davis +11 more
20213 citations
Semantic Scholar
Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers.
R. Lentz, Tyler Friedrich, Jun-Xiao Hu, A. Leal +5 more
20213 citations
Semantic Scholar
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
J. Weiss, A. Nicklawsky, J. Kagihara, D. Gao +8 more
2020Cancer Medicine2 citations Open access
Semantic Scholar
The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible?
A. Oba, C. Lieu, C. Meguid, S. L. Davis +11 more
20202 citations
Semantic Scholar
Abstract 6647: Sensitizing microsatellite stable colorectal cancer to immune checkpoint therapy utilizing Wnt pathway inhibition
S. Bagby, S. Hartman, N. Navarro, Betelehem Yacob +10 more
2020Immunology2 citations
Semantic Scholar
Clinical and molecular characteristics of younger versus older patients with colorectal cancer.
P. Iyer, Kit Wong, C. Lieu, J. Henry +6 more
20182 citations
Semantic Scholar
Abstract A012: Humanized patient-derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC)
A. Capasso, J. Lang, T. Pitts, C. Lieu +7 more
20182 citations
Semantic Scholar
A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
A. Krishnamurthy, A. Dasari, A. C. Lockhart, M. Stein +12 more
20172 citations
Semantic Scholar
2 Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors
A. Patnaik, P. LoRusso, P. Munster, A. Tolcher +9 more
20142 citations
Semantic Scholar
Abstract 4720: Ataxia telangiectasia mutated (ATM) kinase inhibitor AZD0156 in combination with 5-fluorouracil and irinotecan in preclinical models of colorectal cancer
S. L. Davis, Marina I. Schlaepfer, S. Bagby, S. Hartman +11 more
2019Experimental and Molecular Therapeutics1 citations
Semantic Scholar
Abstract A083: A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors
S. L. Davis, E. Lam, B. Corr, C. O'Bryant +14 more
20181 citations
Semantic Scholar
A retrospective review of borderline resectable-locally advanced pancreatic adenocarcinoma (BR-LAPC) undergoing neoadjuvant chemotherapy followed by stereotactic body radiation therapy (SBRT) at the University of Colorado Cancer Center.
Claymore Joey Cuny, J. Hoyle, C. O'Bryant, C. Meguid +4 more
20181 citations
Semantic Scholar
Abstract 1662: Development and validation of humanized mice models implanted with patient derived colorectal cancer xenografts
A. Capasso, J. Lang, T. Pitts, S. L. Davis +8 more
20171 citations
Semantic Scholar
HDAC and PD-1 inhibition in humanized triple-negative breast cancer xenografts.
A. Capasso, J. Lang, T. Pitts, Paul G. Francoeur +8 more
20171 citations
Semantic Scholar
Abstract PR03: Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC
A. Capasso, J. Lang, T. Pitts, S. L. Davis +7 more
20161 citations
Semantic Scholar
Abstract IA20: Challenges, opportunities, and lessons learned in the bench-to-bedside translation of xenopatient studies
S. Eckhardt, T. Pitts, A. Tan, S. Bagby +10 more
20161 citations
Semantic Scholar
Improved Survival With External Beam Radiation Therapy for Patients With Metastatic Esophageal Cancer
C. Rusthoven, A. Amini, Norman Yeh, Matthew W. Jackson +4 more
20151 citations Open access
Semantic Scholar
Abstract B147: Preclinical evaluation of XPO1 inhibition with topoisomerase-I (topo-I) inhibition in colorectal cancer (CRC) cell lines and patient-derived xenograft (PDX) models
R. Lentz, Adrian T A Dominguez, S. Bagby, Cameron A Binns +6 more
2023Molecular Cancer Therapeutics0 citations
Semantic Scholar
1258 Clinical and demographic factors associated with immune related adverse events among those treated with immune checkpoint inhibitors
Savannah Roy, Jun-Xiao Hu, S. L. Davis
2023Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar
Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01).
R. Lentz, Jun-Xiao Hu, P. Blatchford, T. Pitts +8 more
2023Journal of Clinical Oncology0 citations
Semantic Scholar
Targeting Rat Sarcoma Viral Oncogene Homolog for Treatment of Gastrointestinal Cancers
Hannah R. Robinson, S. L. Davis, C. Lieu
2023Advances in Oncology0 citations Open access
Semantic Scholar
Utility of chemotherapy given before and/or after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases.
Tyler Friedrich, Jun-Xia Hu, R. Lentz, A. Leal +7 more
20210 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Lieu×30
Invite
C. Lieu — researcher profile on SciRah
W. Messersmith×25
Invite
W. Messersmith — researcher profile on SciRah
T. Pitts×18
Invite
T. Pitts — researcher profile on SciRah
S. Leong×13
Invite
S. Leong — researcher profile on SciRah

×12

Invite

S. Bagby — researcher profile on SciRah

Invite

A. Leal — researcher profile on SciRah

S. Eckhardt×10

Invite

S. Eckhardt — researcher profile on SciRah

Invite

J. Tentler — researcher profile on SciRah

Invite

J. Diamond — researcher profile on SciRah

Invite

A. Capasso — researcher profile on SciRah

Invite

K. Goodman — researcher profile on SciRah

Invite

J. Lang — researcher profile on SciRah